Drug Discovery Today
Papers 5337
1 page of 534 pages (5,337 results)
#1Sepideh Mirzaei (IAU: Islamic Azad University, Science and Research Branch, Tehran)H-Index: 5
#2Mohammad Hossein Gholami (IAU: Islamic Azad University)H-Index: 3
Last. Gorka Orive (UPV/EHU: University of the Basque Country)H-Index: 68
view all 10 authors...
P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1α, miRNAs, and long noncoding (lnc)RNAs, to reveal their participation in DOX resistance. These antitumor compounds and genetic tools synergistically reduce P-gp expression. Furthermore, ATP depletion impairs P-gp activity to enhance the antitumor activity of DOX. Nanoarchitectures, including liposomes, micelles, pol...
1 CitationsSource
#1Ting Xiang Lim (UQ: University of Queensland)
#2Muneer Ahamed (UQ: University of Queensland)H-Index: 10
Last. David C. Reutens (UQ: University of Queensland)H-Index: 62
view all 3 authors...
Glioblastoma multiforme (GBM) is a deadly disease; 5-year survival rates have shown little improvement over the past 30 years. In vivo positron emission tomography (PET) imaging is an important method of identifying potential diagnostic and therapeutic molecular targets non-invasively. The aryl hydrocarbon receptor (AhR) is a transcription factor that regulates multiple genes involved in immune response modulation and tumorigenesis. The AhR is an attractive potential drug target and studies have...
#1Yue Wu (NCTR: National Center for Toxicological Research)
#2Wenzhong Xiao (Harvard University)H-Index: 46
Last. Minjun Chen (NCTR: National Center for Toxicological Research)H-Index: 30
view all 5 authors...
Drug labeling informs physicians and patients on the safe and effective use of medication. However, recent studies suggested discrepancies in labeling of the same drug between different regulatory agencies. Here, we evaluated the hepatic safety information in labeling for 549 medications approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Limited discrepancies were found regarding risk for hepatic adverse drug reactions (ADRs) (8.7% in hepatic ADR warni...
#1Thomas AdieH-Index: 1
Last. Paul J. RothwellH-Index: 3
view all 8 authors...
The supply of plasmid DNA has become a major bottle neck in the ever-expanding genetic medicine sector. Therefore, the development of new, scalable, faster DNA production technologies is vital for this sector going forward.
#1Maria Camilla Bergonzi (UniFI: University of Florence)H-Index: 30
#2Anna Rita Bilia (UniFI: University of Florence)H-Index: 52
Last. Elisa Landucci (UniFI: University of Florence)H-Index: 18
view all 3 authors...
Psychosis is a high-incidence pathology associated with a profound alteration in the perception of reality. The limitations of drugs available on the market have stimulated the search for alternative solutions to achieve effective antipsychotic therapies. In this review, we evaluate innovative formulations of antipsychotic drugs developed through the application of modern pharmaceutical technologies, including classes of micro and nanocarriers, such as lipid formulations, polymeric nanoparticles...
#1Tristan S. Maurer (Pfizer)H-Index: 26
#2Martin Paul Edwards (Pfizer)H-Index: 20
Last. Charlotte Moira Norfor Allerton (Pfizer)H-Index: 9
view all 5 authors...
Successful small-molecule drug design requires a molecular target with inherent therapeutic potential and a molecule with the right properties to unlock its potential. Present-day drug design strategies have evolved to leave little room for improvement in drug-like properties. As a result, inadequate safety or efficacy associated with molecular targets now constitutes the primary cause of attrition in preclinical development through Phase II. This finding has led to a deeper focus on target sele...
#1Choong Yong Ung (Mayo Clinic)H-Index: 6
#2Taylor M. Weiskittel (Mayo Clinic)H-Index: 2
Last. Hu Li (Mayo Clinic)H-Index: 28
view all 5 authors...
Abstract null null Drug discovery currently focuses on identifying new druggable targets and drug repurposing. Here, we illustrate a third domain of drug discovery: the dimensionality of treatment regimens. We formulate a new schema called ‘Manifold Medicine’, in which disease states are described by vectorial positions on several body-wide axes. Thus, pathological states are represented by multidimensional ‘vectors’ that traverse the body-wide axes. We then delineate the manifold nature of drug...
#1Ting Wang (UU: Utrecht University)H-Index: 2
#2Neil McAuslaneH-Index: 13
Last. Hubert G. M. Leufkens (UU: Utrecht University)H-Index: 85
view all 5 authors...
Abstract null null There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies, enable better trial design, and support the goals of positive HTA recommendation for reimbursement. This study uses information collected directly from companies on individual products to assess their strategies and practices for seeking HTA-related scientific advice in terms of wh...
#1Md. Mahbub Hasan ('KCL': King's College London)H-Index: 6
#2Mark Laws ('KCL': King's College London)H-Index: 3
Last. Khondaker M. Rahman ('KCL': King's College London)H-Index: 21
view all 4 authors...
Abstract null null In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a cytotoxic payload providing the therapy with targeted action against cells expressing a target cell surface antigen. An appropriate choice of mAb is crucial to developing a successful ADC for clinical development. However, problems such as immunogenicity, poor pharmacokinetic (PK) and pharmacodynamic (PD) profiles and variable drug–antibody ratios (DARs) plague ADCs. In this review, we detai...
#1Diana Duarte (University of Porto)H-Index: 4
#2Nuno Vale (University of Porto)H-Index: 26
Abstract null null The drug development process, especially of antineoplastic agents, has become increasingly costly and ineffective. Drug repurposing and drug combination are alternatives to de novo drug development, being low cost, rapid, and easy to apply. These strategies allow higher efficacy, decreased toxicity, and overcoming of drug resistance. The combination of antineoplastic agents is already being applied in cancer therapy, but the combination of repurposed drugs is still under-explo...
Top fields of study
Computational biology
Drug discovery